IDH2 and glioblastoma: Notably, recent studies revealed that several low-grade IDH-wt gliomas with molecular features of glioblastoma are now up-classified to “glioblastoma”, for their aggressive clinical behavior, leading to their reclassification in 2021 WHO guidelines [12].